Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics’ Chief Business Officer Gary Charles Robb reported several bona fide gifts of Corcept Therapeutics common stock and updated his indirect holdings. On May 13, 2026, he gifted 5,300 shares from his direct holdings and two gifts of 1,000 shares each from custodial accounts for a child, totaling 7,300 shares. After these gifts, he directly holds 24,487 shares, while a custodial account for a child holds 12,571 shares and a revocable trust holds 49,716 shares. Footnotes also note unvested restricted stock awards of 997, 251, 224 and 499 shares, each scheduled to vest in full on the one-year anniversary of their respective grant dates if specified conditions are met.
Corcept Therapeutics’ Chief Development Officer William Guyer exercised stock options and sold shares on May 5, 2026. He exercised options to acquire 20,000 shares of common stock at $21.65 per share, then sold 20,000 shares in an open-market transaction at a weighted average price of $51.83 per share, with actual prices ranging from $51.60 to $52.05. Following these transactions, he directly holds 2,231 common shares, which include 224 and 498 shares underlying unvested restricted stock awards that each vest in full one year after their respective grant dates if conditions are met. He also holds 170,000 fully exercisable stock options with a $21.65 exercise price expiring on September 1, 2031. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024.
Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff reported an open-market sale of 40,000 shares of Common Stock on May 1, 2026 at a weighted average price of $50.0965 per share. The transaction was executed indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which he has voting power pursuant to voting agreements.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024. Following this transaction, the trust holds 2,878,326 shares of Corcept Therapeutics Common Stock, for which Belanoff disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics Inc. files a Form 144 reporting an intended sale of 20,000 shares of Common Stock through Stifel Nicolaus & Company Inc. on 05/05/2026 via a stock option exercise for cash. The filing also lists three prior dispositions by William Guyer on 03/04/2026, 03/20/2026, and 04/08/2026 totaling 40,000 shares reported with dollar amounts alongside each sale.
Corcept Therapeutics reported a proposed sale of 40,000 shares of Common Stock under Rule 144 via broker Stifel Nicolaus & Company Inc.. The filing also records a prior sale of 26,198 shares on 03/25/2026 for $1,311,825.
Corcept Therapeutics generated Q1 2026 net product revenue of $164.9 million, up modestly year over year, but swung to a net loss of $31.8 million versus prior profit. The loss reflected sharply higher selling, general and administrative costs of $145.4 million and research and development spending of $66.3 million.
The company ended March 31, 2026 with cash, cash equivalents and marketable securities totaling $515.4 million, providing substantial funding for ongoing programs. In March 2026, the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer, and U.S. sales began in April, adding a new oncology revenue stream alongside Korlym and its authorized generic.
Corcept Therapeutics generated Q1 2026 net product revenue of $164.9 million, up modestly year over year, but swung to a net loss of $31.8 million versus prior profit. The loss reflected sharply higher selling, general and administrative costs of $145.4 million and research and development spending of $66.3 million.
The company ended March 31, 2026 with cash, cash equivalents and marketable securities totaling $515.4 million, providing substantial funding for ongoing programs. In March 2026, the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer, and U.S. sales began in April, adding a new oncology revenue stream alongside Korlym and its authorized generic.
Corcept Therapeutics reported mixed first-quarter 2026 results, combining strong strategic progress with a temporary loss. Revenue rose to $164.9 million from $157.2 million a year earlier, but higher spending on the Lifyorli launch and Cushing’s growth initiatives pushed operating expenses to $214.5 million, resulting in a net loss of $31.8 million, or $0.30 per diluted share, versus net income of $20.5 million in 2025.
The company ended March 31, 2026 with $515.4 million in cash and investments and increased its 2026 revenue guidance to $950–$1,050 million. The FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer in March, and the regimen was added as a preferred option in NCCN Guidelines in April. Corcept also highlighted promising ALS survival data for dazucorilant and expects numerous trial readouts across oncology, Cushing’s syndrome and MASH, while guiding for a return to profitability in the second quarter of 2026.
Corcept Therapeutics reported mixed first-quarter 2026 results, combining strong strategic progress with a temporary loss. Revenue rose to $164.9 million from $157.2 million a year earlier, but higher spending on the Lifyorli launch and Cushing’s growth initiatives pushed operating expenses to $214.5 million, resulting in a net loss of $31.8 million, or $0.30 per diluted share, versus net income of $20.5 million in 2025.
The company ended March 31, 2026 with $515.4 million in cash and investments and increased its 2026 revenue guidance to $950–$1,050 million. The FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer in March, and the regimen was added as a preferred option in NCCN Guidelines in April. Corcept also highlighted promising ALS survival data for dazucorilant and expects numerous trial readouts across oncology, Cushing’s syndrome and MASH, while guiding for a return to profitability in the second quarter of 2026.
Corcept Therapeutics director James N. Wilson, through an entity associated with him, reported a bona fide gift of 2,000 shares of Corcept common stock on April 22, 2026. The gift was made by the James N. Wilson and Pamela D. Wilson Trust and is classified under transaction code G, indicating a non-market transfer with no sale proceeds.
After the gift, that trust still held 1,095,532 shares of Corcept common stock indirectly. The filing also lists additional indirect holdings, including 200,000 shares in the Pamela D. Wilson 2025 Grantor Retained Annuity Trust, 200,000 shares in the James N. Wilson 2025 Grantor Retained Annuity Trust, and 901,067 shares held by James and Pamela Wilson Family Partners. A footnote states that Wilson has voting power over certain entities’ shares under voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.
CORCEPT THERAPEUTICS INC: INGALLS & SNYDER, LLC amended a Schedule 13G to report beneficial ownership of 7,263,466 shares of Common Stock, representing 6.8% of the class as of 12/31/2025. The filing shows shared dispositive power over all reported shares and no sole voting or dispositive power. The amendment is signed on 04/21/2026.
Corcept Therapeutics is asking stockholders to vote at its May 21, 2026 annual meeting on four main items: electing eight directors, ratifying Ernst & Young as auditor, approving executive pay on an advisory basis and amending the 2024 Incentive Award Plan to add more shares.
The proxy details 107,356,686 common shares outstanding as of April 9, 2026 and shows significant 2025 business progress, including revenue rising from $675.0 million in 2024 to $761.4 million and advancement of relacorilant and other cortisol modulators in oncology and metabolic indications. Executive pay is heavily equity-based, with CEO Joseph Belanoff’s 2025 package including $1.19 million salary, a matching $1.19 million bonus and options valued at about $12.9 million.